Fundraising FoxKineta
Seattle, US · Washington corporation · 4 known investors
Find your way into Kineta
Sign up to see every warm intro you have to Kineta
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Kineta team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
RH
Robert HedequistExecutive
PK
Pauline KennyExecutivePauline Kenny is an executive officer at Kineta with a legal background spanning contract negotiations, corporate governance, regulatory compliance, and intellectual property matters.
CM
Charles MagnessNamed on SEC filing
Investors · 4
Keiretsu Forumlisted by Keiretsu ForumSan Francisco East Bay · $250K – $2M
How we know: Keiretsu Forum's portfolio page · Not right? Tell us
TSVClisted by TSVCSilicon Valley · $1M
How we know: the VCSheet dataset · Not right? Tell us
Wellcome TrustreportedLondon
How we know: funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$86.2M disclosed across 18 rounds · 2014–2022
▶$17.4MraisedJun 2022 · 19 investors · BiotechnologyRule 506(b)
▶$17.4MraisedJun 2022 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shawn ladonatoExecutive Officer, Director
- Craig PhilipsExecutive Officer
- Marion R. FooteDirector
- Don MerlinoDirector
- Richard SamuelsonDirector
- Jiyoung HwangDirector
- Steven MitchellDirector
- Raymond BartoszekDirector
- Pauline KennyExecutive Officer
- Offering amount
- $27.3M
- Amount sold
- $17.4M
- Sales commissions
- $900K
- Placement agents
- Alta Companies Ltd.
- First sale
- May 2021
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$2.4MraisedMar 2022 · 1 investors · BiotechnologyRule 506(b)
▶$2.4MraisedMar 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Don MerlinoDirector
- Craig PhilipsExecutive Officer
- Raymond BartoszekDirector
- Marion R. FooteDirector
- Shawn ladonatoExecutive Officer, Director
- Richard SamuelsonDirector
- Kyungwon OhDirector
- Pauline KennyExecutive Officer
- Steven MitchellDirector
- Offering amount
- $15M
- Amount sold
- $2.4M
- Sales commissions
- $256K
- Placement agents
- Alta Companies Ltd.
- First sale
- Feb 2022
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$1.2MraisedJul 2021 · 11 investors · BiotechnologyRule 506(b)
▶$1.2MraisedJul 2021 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Marion FooteDirector
- Richard SamuelsonDirector
- Don MerlinoDirector
- Steven MitchellDirector
- Shawn ladonatoExecutive Officer, Director
- Kevin OhDirector
- Raymond BartoszekDirector
- Pauline KennyExecutive Officer
- Craig PhilipsExecutive Officer
- Offering amount
- $3.8M
- Amount sold
- $1.2M
- First sale
- Jun 2021
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$3.3MraisedNov 2020 · 21 investors · BiotechnologyRule 506(b)
▶$3.3MraisedNov 2020 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Raymond BartoszekDirector
- Pauline KennyExecutive Officer
- Craig PhilipsExecutive Officer
- Shawn IadonatoExecutive Officer, Director
- Marion R. FooteDirector
- Richard SamuelsonDirector
- Don MerlinoDirector
- Steven MitchellDirector
- Offering amount
- $3.5M
- Amount sold
- $3.3M
- First sale
- Jan 2017
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$5MraisedNov 2020 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedNov 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shawn IadonatoExecutive Officer, Director
- Craig PhilipsExecutive Officer
- Pauline KennyExecutive Officer
- Marion R. FooteDirector
- Richard SamuelsonDirector
- Don MerlinoDirector
- Raymond BartoszekDirector
- Steven MitchellDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Sep 2017
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$3MraisedNov 2020 · 9 investors · BiotechnologyRule 506(b)
▶$3MraisedNov 2020 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shawn ladonatoExecutive Officer, Director
- Craig PhilipsExecutive Officer
- Pauline KennyExecutive Officer
- Marion R. FooteDirector
- Richard SamuelsonDirector
- Don MerlinoDirector
- Raymond BartoszekDirector
- Steven MitchellDirector
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Oct 2019
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$9MraisedNov 2020 · 2 investors · BiotechnologyRule 506(b)
▶$9MraisedNov 2020 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shawn IadonatoExecutive Officer, Director
- Craig PhilipsExecutive Officer
- Don MerlinoDirector
- Raymond BartoszekDirector
- Pauline KennyExecutive Officer
- Marion R. FooteDirector
- Steven MitchellDirector
- Richard SamuelsonDirector
- Offering amount
- $9M
- Amount sold
- $9M
- First sale
- Sep 2017
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$100KraisedJun 2020 · 1 investors · BiotechnologyRule 506(b)
▶$100KraisedJun 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard SamuelsonDirector
- Steven MitchellDirector
- Pauline KennyExecutive Officer
- Craig PhilipsExecutive Officer
- Shawn IadonatoExecutive Officer, Director
- Don MerlinoDirector
- Marion FooteDirector
- Raymond BartoszekDirector
- Offering amount
- $10M
- Amount sold
- $100K
- First sale
- Jun 2020
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 8 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2011 | $2.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $599.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $585.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- Who founded Kineta?
- Kineta was founded by Shawn Iadonato.
- Who are Kineta's investors?
- Kineta's investors include Keiretsu Forum, Pfizer Venture Investments, TSVC, Wellcome Trust.
- How much funding has Kineta raised?
- Kineta has disclosed $86.2M raised across 18 rounds.
- Where is Kineta headquartered?
- Kineta is headquartered in Seattle, US.